Malignant ascites accounts for about 10% of all cases of ascites and is usually caused by ovarian, endometrial, breast, esophageal, gastric, colorectal, lung, pancreatic, hepatobilliary and primary peritoneal carcinomas. In pleural effusions and ascites, excess fluid that can no longer be removed accumulates inside the body. Patients can complain of increasing abdominal girth, generalized abdominal pain and shortness of breath. In the united states, ascites is most often due to portal hypertension resulting from cirrhosis. Mar 28, 2006 the purpose of this study was to determine risk factors for development of malignant ascites and its prognostic significance in patients with pancreatic cancer. Paracentesis is indicated for those patients who have symptoms of. Several pathophysiological mechanisms are implicated in the development of malignant ascites. Abstract several pathogenic processes have been implicated in the development of abdominal ascites.
Patients may have a history of metastases to the peritoneum or liver, enlarged abdominal lymph nodes, or a large tumor burden prior to the development of ascites. Of these 22, 16 had complete and six had partial resolution of. While 1 year survival in patients who develop ascites is 85%, it decreases to 25% once it has progressed to hyponatraemia, refractory ascites or hrs 4. Patients with non malignant ascites had an average age of 57. The denver ascites shunt is a peritoneovenous shunting system that can help relieve symptoms of ascitic fluid buildup. A survey of practice in management of malignant ascites.
Guidelines for the management of malignant ascites. Malignant ascites signals end stage events in a wide spectrum of cancers and is associated with significant morbidity. Ascites is the accumulation of fluid in the peritoneal cavity. These problems may occur when too much fluid builds up in the abdominal cavity. Guidelines for the management of malignant ascites st peters. Mixed ascites occurs in 5% of cases when the patient has two or more separate causes of ascites formation, usually due to cirrhosis and infection or malignancy. The fluids that build up in the gut as a result of ascites could become infected with bacteria. Both intra and extraabdominal cancers can cause formation of ma, and in 80% of the cases breast, ovarian, endometrial, gastrointestinal, or pancreatic cancer is the primary. Management of malignant ascites ovarian cancer cancer. Prognostic significance of new onset ascites in patients with.
Predictors of poor prognosis in patients with malignant. Malignant ascites an overview sciencedirect topics. Ascites with myxedema appears to be secondary to hypothyroidismrelated cardiac failure. The pathophysiology is multifactorial and include reduction of lymphatic drainage from the peritoneal cavity and increased vascular permeability. Management of drainage for malignant ascites in gynaecological. Successful treatment of ascites depends upon an accurate diagnosis of its cause table 1 and table 2 and table 3 and algorithm 1. Malignant effusion is the escape of fluid from the blood or vessels into tissues or cavities. Management of adult patients with ascites due to cirrhosis. Ascites should be drained every 1 to 2 days, depending upon need and the physicians instructions. Barni s, cabiddu m, ghilardi m, petrelli f 2011 a novel perspective for an orphan problem. Research article open access management of nonovarian cancer malignant ascites through indwelling catheter drainage xiaoli gu1,2, yuanyuan zhang1,2, menglei cheng1,2, minghui liu1,2, zhe zhang1,2 and wenwu cheng1,2,3 abstract backgrounds.
Patients with ascites present with distended abdomen, difficulty mobilising, shortness of breath, fatigue and altered bowel habit. Almost in 20% of cases with malignant ascites tumor is of unknown origin and mostly protein content is high in malignant ascites. Malignant ascites is a formation of fluids and cancer cells in the abdominal cavity. Ct or ultrasound can confirm clinical suspicion of ascites, with the latter often used for marking an appropriate site for paracentesis. The true prevalence and incidence of cirrhosis of the liver and its complications in the uk are unknown. Management of ascites in ovarian cancer patients rcog. Patients with ascites present with distended abdomen, difficulty mobilising. Jan 25, 2014 approximately 85% of patients with ascites have cirrhosis, past history of cancer, heart failure, or tb.
Nonmalignant causes of ascites include liver disease, congestive cardiac failure, nephrotic syndrome, pancreatitis, tuberculosis and bowel perforation. Management of drainage for malignant ascites in gynaecological cancer. The discovery of ascites in an oncologic contest is always difficult, the problem being to differentiate between cirrhotic and malignant ascites. In addition, lymphoma can be complicated by chylous ascites. Malignancyrelated ascites is frequently painful, whereas cirrhotic ascites is usually. A recommendation for further research is a randomized controlled trial comparing the use of diuretics with paracentesis in the management of malignant ascites. Paracentesis is indicated for those patients who have symptoms of increasing intraabdominal pressure.
Malignant ascites is a common condition in patients exhibiting an intraperitoneal tumor spread. Influence of tumor type ascites typically develops in the setting of recurrent andor advanced cancer. Jun 20, 2008 the non malignant forms stem from congestive heart failure, chirosis of the liver, and problems with regards to tuberculosis in the lungs. Malignancyrelated ascites may be seen with several tumors, including malignancies of the ovary, breast, colon, lung, pancreas, and liver. The management of malignant ascites in palliative care. Successful treatment of ascites depends upon an accurate diagnosis of its cause table 1 and table 2 and table 3 and. The overall sensitivity of cytology for the detection of malignancyrelated ascites is 5875%. There is a common misconception that malignancyrelated ascites is synonymous with peritoneal carcinomatosis 2. At present, there is insufficient data regarding the best management of drainage for malignant ascites among women with gynaecological cancer. Paracentesis is widely employed for palliation of symptomatic malignant ascites. Most women with advanced ovarian cancer and some women with advanced endometrial cancer need repeated drainage for ascites. A prospective database was queried to identify patients with pancreatic cancer who develop ascites.
The goal of management remains early diagnosis and treatment of symptoms and improvement of quality of life without the intention to cure the disease. Ascites is an accumulation of fluid within the peritoneal cavity of the abdomen and can occur in association with many conditions such as cirrhosis of the liver. Ascites in ovarian cancer patients, management of scientific. I can tell you what my husbands experience was with the ascites, but please do not give up hope. Malignant ascites definition of malignant ascites by. Guidelines to advise those involved in the drainage of ascites are usually produced locally and are generally not evidencebased but mainly based on clinicians anecdotal evidence and experience. Ct is useful to confirm the mechanism of ascites formation, assessing the peritoneum, portal vein and liver. It is a frequent cause of morbidity, causing intractable nausea, anorexia, dyspnea, and painful abdominal distension, all of which markedly reduce a patients quality of life. Malignant ascites ma is defined as abnormal accumulation of fluid within the peritoneal cavity caused by the intraperitoneal spread of original cancer. The clinical management of abdominal ascites, spontaneous. Management of ascites due to gastrointestinal malignancy ncbi. Oct 19, 2016 malignant ascites is an indicator of endstage disease. Pdf malignant ascites is an ominous sign that indicates peritoneal metastasis of the primary malignancy.
The pleurx peritoneal catheter system is indicated for intermittent drainage of symptomatic, recurrent, malignant ascites that does not respond to medical management of the underlying disease. The management of malignant ascites is a significant challenge in gastrointestinal medical oncology. When the ascites occurs as a result of some malignancy or cancer, then it is known as malignant ascites. Guidelines for the management of malignant ascites yumpu. Furthermore, 5% of cases are socalled mixed ascites, since they combine several causes. Malignant ascites is an ominous sign that indicates peritoneal metastasis of the primary malignancy. Alison keen, debbie fitzgerald, andrew bryant, heather o dickinson. Portal hypertension, most usually in the context of liver cirrhosis, can explain about 75% of the cases, whereas infective, inflammatory and infiltrative aetiologies can account for the rest. Malignant disease can cause ascites by at least six mechanisms. The main differential diagnosis is malignant ascites, which represents 10% of cases of ascites. A recent survey 16 examined physician attitude toward management of malignant ascites and concluded that paracentesis was used by 98% of physicians and diuretics were used by 61%.
The average survival after development of malignant ascites is only about 5 months. Palliative treatment of malignant ascites palliative. Most patients with advanced ovarian cancer and some patients with advanced endometrial cancer need repeated drainage for malignant ascites. In the absence of malignancy, liver disease is responsible for over 80% of cases of ascites. In the management of ovarian cancer the detection of malignant cells in ascitic fluid is important for staging and has been found to have prognostic significance. In most cases of malignancyrelated ascites, the prognosis is poor and treatment of. Management of ascites due to gastrointestinal malignancy. Malignant ascites ma accompanies a variety of abdominal and extraabdominal tumors. Current treatment strategies include diuretic therapy, paracentesis, peritoneal drains, and venous shunts. Peritoneovenous shunting in the management of malignant.
Malignant ascites, cancers, performance status, paracentesis, chemotherapy, poor prognosis, survival. Mainstays of treatment include diuretics and recurrent large volume paracentesis. Excess peritoneal fluid evoked by malignancy, which causes subdiaphragmatic lymphatic obstruction e. Malignant ascites fluid overload cancer survivors network.
Surveys of practices in management of malignant ascites from england 3 and. The goal of our study was to evaluate the technical. Malignant ascites associated with carcinoma of the prostate muhammad wasif saif,md university of alabama at birmingham uab,comprehensive cancer center,birmingham, alabama patients with history of prostate cancer develop malignant effusions,prostate specific antigen psa immunohistostaining of the fluid can serve as a. Octreotide as an agent for the relief of malignant ascites in palliative care patients. Malignant ascites, which is found in 10% of cases, is commonly because of peritoneal metastasis in neoplastic disease, but it is more common with ovary, breast, gastric, pancreatic, bronchus or colon cancer. Know the symptoms, diagnosis and treatment of ascites. Cancers commonly associated with the development of ascites include breast, colorectal, endometrial, gastric, ovarian and pancreatic cancer. The denver ascites shunt from carefusion is designed to give you and your patients an alternative to conventional therapy in managing retractable ascites. Ma can result in impairment in quality of life qol and significant symptoms. Malignant ascites ma is a pathological condition caused by cancer. Apr 21, 2016 intraabdominal placement of the central venous catheter cvc was conducted to manage the ascites related symptoms of nonovarian cancer patients. Background malignancy is the underlying cause in approximately 10% of all cases of ascites. However, there are no established evidencebased guidelines, and there is a lack of randomized controlled trials identifying optimal therapy.
In peritoneal carcinomatosis, the most common cause of malignant ascites, the leakage of protein rich fluid from the malignant cells causes exudation of extracellular fluid into the peritoneal cavity. Intraabdominal placement of the central venous catheter cvc was conducted to manage the. This page provides more information about how pleural effusions and ascites occur, what. Are you sure that your mother had malignant ascites since this form of ascites is traces backt o some underlying from of cancer, usually in the peritonium i would find this out first. Conclusion malignant ascites indicates the presence of malignant cells in the peritoneal cavity and is a grave prognostic sign. Fibrinolysis in the management of malignant ascites and. Treatment focuses on palliation of symptoms, although effective palliation is difficult to achieve. Guidelines on the management of ascites in cirrhosis. A condition in which fluid containing cancer cells collects within the abdomen. Approach to the patient with ascites differential diagnosis. In a pleural effusion, the fluid accumulates in the space between the lungs and ribs. Thus, the phrase malignancyrelated ascites is a more appropriate descriptor than malignant ascites since it includes all of these causes. The current and future management of malignant ascites. In those very near the end of life, there may be safer ways to control symptoms.
Stage at presentation, size, and location of primary tumor, treatment received and length of survival after onset of ascites were. Update 2012 2012 the american association for the study of liver diseases, all. Routinely, a cell count and differential should be performed on ascitic. Unfortunately, my husband mike 54 when diagnosed june 21, 2010 had stage iv stomach cancer with mets to the bones not extreme mets and never really gave him any pain, thank god. In some patients, there is rapid reaccumulation of fluid necessitating frequent repeat procedures. This may limit a patients ability to eat, walk and perform daily activities. Basic medical management of malignant ascites includes diuretics and therapeutic paracentesis. Malignant ascites current treatment and novel therapeutic options. Ma has several symptoms, producing a significant reduction in the patients quality of life.
Bsg guidelines on the management of ascites in cirrhosis. Peritoneovenous shunting in the management of malignant ascites albert k. Management of nonovarian cancer malignant ascites through. Chronic peritoneal indwelling catheters for the management.
Patients with malignant ascites can sometimes have portal hypertension and functional cirrhosis based on tumor burden, which can make the decision on whether or not to administer albumin. Although lymphatic obstruction has been considered the major pathophysiologic mechanism behind its. Malignant ascites ma is a sign of advanced cancer and poor prognosis. Ascites is the most common complication of cirrhosis and is associated with a poor quality of life, increased risks of infections and renal failure, and a poor longterm outcome. In peritoneal carcinomatosis, the most common cause of malignant ascites, the leakage of protein rich fluid from the malignant cells causes exudation of. Itsonset and progression is associated with deterioration in quality of life qol and a poor prognosis.
The chief factor contributing to ascites is splanchnic vasodilatation. Ascites is the pathologic fluid accumulation within the peritoneal cavity. Guidelines in the management of symptomatic malignant ascites in advanced cancer. Malignant ascites is defined as the abnormal accumulation of fluid in the peritoneal cavity of patients with malignancies of the ovaries, breast, colon, lung, pancreas, stomach or liver. Clinical findings abdominal distension, weight gain, indigestion, dyspnea, orthopnea, tachypnoea, intestinal obstruction with nausea, vomiting. Patients who suffer from this are usually on the final stage of their cancer events. History and physical examination in the united states, in approximately 85% of patients with ascites, cirrhosis is the cause, but 15% have a non. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Read more about symptoms, diagnosis, treatment, complications, causes and. Shapiro, md \sb\the incapacitating, malignant ascites of 37 patients were treated with peritoneovenous shunt using the leveen valve.
An audit of clinical practice and development of standards and guidelines. Clinical features and management of malignant ascites pages with reference to book, from 38 to 40 imtiaz malik, saleem abubakar, feroz alam, ata khan department of medicine, the aga khan university, karachi. Therefore, the guiding principle for management of malignant ascites should be. Mar 31, 2012 malignant ascites ma accompanies a variety of abdominal and extraabdominal tumors. Abdominal pain, discomfort and difficulty breathing. It is a primary cause of morbidity and raises several treatment challenges. A guideline on the management of symptomatic malignant ascites by abdominal. Indwelling catheters for the management of malignant ascites. Malignant ascites is a manifestation of advanced malignant disease that is associated with significant morbidity. Malignant ascites abnormal accumulation of fluid in the peritoneal cavity is a manifestation of end stage events in a variety of cancers and associated with significant morbidity. Easl clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis pdf 04 august 2010 publisher. Technically, it is more than 25 ml of fluid in the peritoneal cavity. Both clinical pictures are consequences of various diseases. Aasld practice guideline management of adult patients with ascites due to cirrhosis.
Symptoms may include increased abdominal size, increased weight, abdominal discomfort, and shortness of breath. The prognosis of this disease is poor as the patients often succumb within four months after the diagnosis. Malignant ascites is the buildup of large volumes of fluid in the peritoneal cavity secondary to cancer. It accounts for about 10% of all cases of ascites and usually caused by ovarian, breast, oesophageal. Upon closer examination of the abdomen, patients with malignant ascites may have increased dullness to percussion or shifting dullness. Ascites is a common sign of several diseases, both benign and malignant, and often contributes to more symptoms than the underlying pathology itself. About 1550% of patients with malignancy will develop ascites. While the pathophysiology of malignant ascites is not totally understood, factors that contribute to the development of ascites include lymphatic obstruction by tumor cells, excess vascular permeability, and hormonal effects, as well as other tumorspecific effects such as excess metalloproteinase production. Ma is usually a sign of endstage illness that is accomplanied by abdominal pain, discomfort, anorexia, nausea, and dyspnea. Women often wait for as long as possible before seeking intervention, or are advised by health care professionals to wait for drainage until there is a large enough volume of fluid to ensure.
Malignancy is the underlying cause in approximately 10% of all. The majority 75% of patients who present with ascites have underlying cirrhosis, with the remainder being due to malignancy 10%, heart failure 3%, tuberculosis 2%, pancreatitis 1% and other rare causes. Patients may have a history of metastases to the peritoneum or liver, enlarged abdominal lymph. Palliation ofascites was achieved in 27 37 patients until they died of their underlying diseases. These guidelines are based on a comprehensive literature search, including the results of rando. Accumulation of fluid within the peritoneal cavity results in ascites. Malignant ascites in patients with terminal cancer is. Current treatment options behrendt, r robert wood johnson university hospital, new brunswick, nj. Iffat rizwana, javaid rizvi department of obstetricsgynaecology, the aga khan university, karachi. How valuable is ascitic cytology in the detection and. Most studies used pleurx or tenckhoff tunneled catheters. The mean survival time for patients with malignant ascites is less than 4 months, depending on the underlying cancer. Patients with advanced ovarian cancer and some patients with advanced endometrial cancer often need repeated drainage for malignant ascites jatoi 2005.
1221 478 1168 444 237 1506 479 681 121 974 402 1054 1095 1121 1117 518 1563 522 207 943 617 1530 410 1529 484 1563 1168 755 1252 745 299 1404 971 1026 328 1298 1429 1192 1002 256 409 847 1461